Cell-based therapy is being promoted as a novel approach to repairing damaged tissues of the head and neck and improving feeling in patients with multiple sclerosis. In a retrospective study published in the journal JAMA Neurology Cardio Oncology Fellowship members from the University of Geneva (Switzerland) Sigma Italiano di Milano (Italy) Lackland Biotest (Belgium) and the University Hospitals of Geneva (Switzerland) screened 10 cancer patients with MSX-related lesions including those with transient penetrance (who would not yet require treatment) and identified the presence of tiny amounts of a protein that plays a key role in the memory-processing mechanisms of the peripheral nervous system not yet activated by stimulation.

Although some research has already been performed in animals there was no human trial to verify the effectiveness of cell-based therapy. Since the possibility of cell therapy cannot be ruled out research groups at the University Hospitals of Geneva (Switzerland) the University Hospitals of Leuven (Belgium) the Italian Centre for NeuroimmunologyImmune Acceptance (CNA) and the University of Trento (Italy) have taken part in the first systematic human clinical trials of the potential therapy dubbed PheREMGr9 by the scientists of the University Hospitals of Geneva the University Hospitals of Leuven and the University of Nantes (France). According to the scientists their results show that the therapy has shown impressive efficacy in patients with two neuroimmunological features: the activation of sebrels (plasmacytoid dendritic cells) and the loss of axons (proteins that carry signals between neurons)In a first-patient study the scientists performed multifocal transcranial magnetic stimulation therapy (TMS) in subjects suffering from a transient lesion in the optic nerves which is called non-recurrence Stroke. The therapeutic effect was observed in post-stimulation periods of about 10 days compared to a 15-day opportunistic non-treated control period of about four weeks explained the neurosurgeon. The trial was conducted at six hospital centers and lasted for 36 to 90 days. We demonstrated an effective therapeutic effect with a therapeutic duration of 40 to 100 days. Commenting on the trial results Professor Flavio Zanggutis of the University of Geneva the neurosurgeon clarified: The study is a first step toward relaying knowledge gained from patient experience to the clinical development of cell-based therapies for patients with pre-existing lesions. In fact this new finding is expected to provide important information on the efficacy of cell-based therapy in patients with the two neuroimmunological features that made this a successful trial. He pointed out that in cancer patients it was found that the efficacy of the stem cell therapy stem cell therapy with total human derived mesenchymal stem cells injected into the skin of a patient was 62 versus 41 for those who received cell therapy delivered through catheters.

The next steps involve larger numbers of patients who are being treated with pharmaceuticals or a combination of what we already see and evaluate in this trial the lung cancer specialist added.

This suggests that we should not underestimate the potential of cell-based therapies for the treatment of patients with neuroimmunological diseases in general he noted.

The research was supported by the National Institutes of Health (R01 NS057607 NS09465 NS047387) a Geneva resident and the Swiss V-Train Foundation.